Gremubamab
Based on 1 publication(s) in Google Scholar
Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 98.40%
- CAS 番号: 1800381-36-5
- 分子量:200.46 kDa
-
保管条件:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
MedChemExpress(MCE)の使用を引用している文献 Gremubamab
More
生物活性
製品説明
Isotype
[VH-CH1-scFv-VH-VK-h-CH2-CH3_L-kappa]2
Recommend Isotype Controls
Species Reactivity
Pseudomonas aeruginosa
IC50 & Target
PcrV & PslG
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Rabbits (acute pneumonia model)[2]
-
Dosage:1, 5, 15 mg/kg
-
Administration:I.v.; at 1 h postinfection
-
Result:Improved survival outcomes in a dose-dependent manner in a rabbit acute pneumonia model.
遺伝子ID
アクセッション番号
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
[VH-CH1-scFv-VH-VK-h-CH2-CH3_L-kappa]2
アプリケーション
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Pseudomonas aeruginosa can bind Gremubamab. The EC50 for this effect is 136.6 ng/mL.
化学情報
-
CAS 番号 1800381-36-5
-
性状 Liquid
-
分子量 200.46 kDa
-
Color Colorless to light yellow
-
SMILES
[Gremubamab]
-
別名
MEDI3902
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Antimicrob Agents Chemother
XAB06, a glyco-humanized broad-spectrum anti- Pseudomonas aeruginosa polyclonal antibody, protects mice in a lethal sepsis model. [Abstract]2026 Sep 3:e0027726. PMID: 42690181
純度とドキュメンテーション
-
データシート (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Chastre J, et al. Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial. Crit Care. 2022 Nov 15;26(1):355. [Content Brief]
[2]. Le HN, et al. Treatment Efficacy of MEDI3902 in Pseudomonas aeruginosa Bloodstream Infection and Acute Pneumonia Rabbit Models. Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00710-19. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)